Pain Management Market to grow at a CAGR of 4.95% during 2026 to 2035; Driven by Rising Prevalence of Chronic Pain and Increasing Demand for Advanced Pain Management Solutions

Market Research Future (MRFR) has updated the report on the global Pain Management Market, valuing the market at USD 87.65 billion in 2025 and projecting it to grow from USD 91.82 billion in 2026, reaching USD 139.80 billion by 2035 at a compound annual growth rate (CAGR) of 4.95% during the forecast period 2026--2035.

The market is being transformed by the US CDC’s updated Clinical Practice Guideline for Prescribing Opioids, the European Commission’s Pharmaceutical Strategy, which includes EUR 1.2 billion for R&D of non-addictive analgesics, and payer systems increasingly linking reimbursement to durable functional outcomes over prescriptions.

Market Overview

The market is transitioning from conventional opioid-centric treatment paradigms to integrated platforms incorporating non-pharmacological pain relief modalities and AI-driven dosing algorithms, hence making pain management a strategic imperative for healthcare systems globally. The convergence of innovation in neuromodulation devices, digital therapeutics, and multimodal analgesia strategies is revolutionizing the landscape of chronic pain therapy. It is creating a fertile growth environment for pharmaceutical companies, device manufacturers, and digital health platforms globally.

The North American region accounts for an approximate share of 35.4% in the global market due to the well-established insurance infrastructure and the high per-capita spending on chronic pain therapy. Europe has a global share of about 28.6%, supported by streamlined regulatory routes for pain management devices under the EU MDR framework. Asia-Pacific is the fastest-growing area with an estimated CAGR of 11.5% through 2035, spurred by increased health insurance coverage in India and updates to China’s national essential medications list.

Key Market Trends & Growth Drivers

• Aging Population and Chronic Disease Burden: WHO projections indicate that by 2050 there will be 2.1 billion persons over 60, about twice as many as there were in 2020. Treatment for chronic pain should continue. The main causes are age-related illnesses such as diabetic neuropathy, osteoarthritis, and post-surgery pain. Chronic pain affects around 51 million persons in the United States, according to the National Institutes of Health, and costs the country between USD 560 and USD 635 billion a year in direct medical costs and lost productivity. This demographic pressure assures the baseline increase of the Pain Management Market regardless of the technology cycles.


• Regulatory Movement Towards Multimodal Analgesia Strategies: The CDC’s 2022 Clinical Practice Guideline specifically recommends a multimodal approach to analgesia as a first-line treatment, decreasing the initiation of opioid analgesic treatment for chronic non-cancer pain. CMS also simultaneously rolled out bundled payment methods that incentive hospitals to use non-pharmacological pain treatment prior to dispensing opioids. In Europe, the EMA’s Opioid Action Plan (2023), which implemented risk-evaluation and mitigation strategies in 27 member states, hastened the demand for interventional pain procedures and device-based alternatives.


• Neuromodulation & Device Innovation: Global sales of spinal cord stimulation exceeded USD 3.2 billion in 2024, and Abbott and Medtronic’s closed-loop systems showed >50% superiority in pain alleviation compared to open-loop versions in randomized controlled studies. The FDA’s Breakthrough Device Designation pathway has accelerated approval times for next-generation neuromodulation platforms by 12–18 months, creating a vibrant innovation environment. 14 US commercial payer plans now cover high-frequency stimulation and dorsal root ganglion therapy, up from only five in 2020.


• Digital Health and AI Integration: The latest frontier in the Pain Management Market is AI-driven dosage algorithms. Companies such as Kaia Health and PainScale have FDA clearances for prescription digital therapeutics that combine cognitive behavioral therapy modules with real-time biometric monitoring. A 2024 JAMA study found AI-assisted tapering of opioid analgesic medication lowered average morphine milligram equivalents by 37%, without affecting pain levels. In Germany and the UK, payers are testing value-based agreements that link digital therapeutic reimbursement to functional outcomes at 90 days.


• Emerging-market insurance expansion: India’s Ayushman Bharat scheme now covers 500 million beneficiaries, and China’s National Healthcare Security Administration expanded chronic pain therapy reimbursement categories in 2024. These governmental actions will unleash demand from populations that previously relied on OTC analgesics, creating a greenfield opportunity for branded non-narcotic analgesics and entry-level neuromodulation devices in the Pain Management Market.

Market Segmentation Insights

By Mode of Pain Management: Drugs held approximately 73.5% of the Pain Management Market in 2025, underpinned by established distribution channels for opioid analgesic treatment and non-narcotic analgesics. Devices are forecast to record the fastest CAGR of 10.8% through 2035, as neuro-modulation platforms gain traction across interventional pain procedures. Opioids account for 41.0% market share, sustained by post-surgical and cancer pain demand. Non-narcotic analgesics reached USD 28.50 billion in 2025, driven by chronic pain therapy in primary care.

By Application: Neuropathic pain led with a 34.2% revenue share in the Pain Management Market during 2025, driven by rising diabetic neuropathy prevalence. Facial pain and migraine therapies are set to expand at a 9.4% CAGR to 2035, fueled by CGRP-inhibitor adoption and non-pharmacological pain relief devices. Cancer pain management accounted for approximately USD 20.9 billion in 2025.

By Setting of Care: Hospitals represented 66.8% of total revenue in 2025, reflecting the concentration of interventional pain procedures in acute-care settings. Ambulatory Surgical Centers generated USD 12.40 billion, benefiting from CMS reimbursement parity expansion. Home-care settings are projected to grow at a 12.5% CAGR through 2035 as remote monitoring and chronic pain therapy decentralization accelerate.

By Route of Administration: Oral delivery dominates drug-based pain management, reflecting patient preference and established reimbursement. Injectable formats support hospital-based interventional pain procedures and device implantations. Transdermal patches and topical agents are gaining share as non-pharmacological pain relief alternatives for localized chronic pain therapy.

Regional Landscape

North America -- Technology Adoption Leader

North America is the largest market for Pain Management, with over 35.4% of the global market share. The region is experiencing growth due to the world’s largest commercial insurance ecosystem, the highest per capita spend on interventional pain procedures, and the CDC guideline-driven shift to multimodal analgesia approaches. The US accounts for 82.3% of the regional revenue. The region is backed by the Substance Abuse and Mental Health Services Administration (SAMHSA), which has earmarked USD 7.4 billion in FY2024 for opioid-response programs, thereby indirectly propelling the demand for non-pharmacological pain relief alternatives. Canada is also a major player, with the 5.1% CAGR being driven by the federal opioid stewardship programs. Growth market Mexico with IMSS system piloting neuromodulation access in 12 specialist institutions and USD 1.85 billion in 2025.

Europe -- Emerging Market Dynamics

Europe constitutes about 28.6% of the global market, owing to harmonized regulatory pathways under the EU Medical Device Regulation, the European Commission's Pharmaceutical Strategy allocating EUR 1.2 billion for non-addictive analgesic R&D, and cross-border health technology assessment cooperation. With a 24.8% regional share, Germany is leading the way in regional adoption aided by its pioneering DiGA fast-track approach for digital chronic pain therapy approvals. UK (5.3% CAGR) is encouraged by NHS pain management pathway reform and NICE recommendations promoting multimodal methods to analgesia vs. long-term opiate monotherapy. France, Italy and Spain make up the biggest markets, with the Nordic countries being at the forefront of early adoption of non-pharmacological pain treatment technology. Big firms like Pfizer and Abbott Laboratories are powering innovation, as are a burgeoning number of digital pharmaceuticals startups making the battle even more fierce.

Asia-Pacific: Rapid Growth and Innovation

Asia-Pacific is the fastest-expanding area in the Pain Management Market with an estimated CAGR of 11.5% through 2035. Growth is fuelled by demographic ageing in Japan and South Korea, large insurance enrollment drives in India and China and increasing availability of non-pharmacological pain relief modalities. China has a 38.5% regional share, 14th Five-Year Plan allocates CNY 22 billion to pain-specialty departments in county hospitals. India trails at a 13.2% CAGR, with the National Programme for Palliative Care broadening access to chronic pain therapy to tier-2 and tier-3 cities under Ayushman Bharat’s coverage of 500 million beneficiaries. Japan and South Korea are leading in terms of aging demography and robotic surgery integration. Japan is projected to generate USD 4.50 billion in 2025.

Middle East and Africa -- Untapped Market Potential

Globally, the Middle East and Africa area is a smaller but growing market segment. Growth is being driven by investments in healthcare infrastructure and an increased demand for solutions to manage chronic pain. Saudi Arabia has the largest stake in the region at 32.5%, with 16 new rehabilitation and pain management centers as part of Vision 2030. The UAE capitalises on its medical-tourism posture, luring patients seeking modern multimodal analgesia options, which are lacking in neighbouring countries. South Africa’s National Health Insurance system is projected to boost access to non-pharmacological pain management in underserved communities. Egypt’s Universal Health Insurance phase-in propels 7.2% CAGR.

Competitive Landscape

The global Pain Management Market is moderately concentrated, with the top five players accounting for an estimated 32-38% of the overall revenue. Some of the major players in the market arePfizer Inc., Johnson & Johnson, Abbott Laboratories, Medtronic plc, Novartis AG, Teva Pharmaceutical, Boston Scientific Corp., Eli Lilly & Co., Nevro Corp., and Haleon plc. Notable recent developments include

• Abbott Laboratories got FDA approval for its Proclaim XR next-generation closed-loop spinal cord stimulator with AI-adaptive algorithms in March 2025, encouraging non-pharmacological pain management technology in the Pain Management Market.


• Pfizer Inc. showed its commitment to alternatives to opioid analgesic treatment by announcing a USD 1.8 billion licensing agreement in January 2025 for a non-opioid sodium channel inhibitor for chronic pain therapy.


• In October 2024, Medtronic plc launched the Inceptiv closed-loop recharge-free neurostimulator in Europe, providing additional options for multimodal analgesia approaches for neuropathic pain patients.


• Kaia Health’s digital therapeutic prescription for persistent low back pain received US FDA clearance in July 2024, a milestone for AI-driven chronic pain medication.


• Novartis AG completed enrollment in its Phase III ELEVATE trial in April 2024, evaluating a next-generation CGRP antibody for episodic migraine, supporting the facial pain and migraine segment of the Pain Management Market.


• Boston Scientific’s acquisition of a majority share in a radiofrequency ablation firm for USD 450 million in February 2024 added to its interventional pain therapies portfolio.


• The European Commission launched the EU Action Plan on Pain Management in November 2023, dedicating EUR 800 million to non-pharmacological pain management research in member states until 2028.


• September 2023: Nevro Corp. showed 24-month data from the SENZA-PDN study of durable effectiveness of high-frequency stimulation in painful diabetic neuropathy, a major indication in chronic pain therapy.

Future Outlook

The Pain Management Market is expected to be reshaped by 2035 by further advancements in closed-loop neuromodulation platforms with embedded NFC tags and Bluetooth-enabled dose-tracking sensors, expanded prescription digital therapeutics and platform economics, and deepening penetration into emerging markets across Asia-Pacific, the Middle East and Africa. Companies focused on AI-enabled precision pain management, decentralization of interventional pain procedures to ambulatory and home settings, and ESG-driven reallocation of capital away from opioid exposure are well-positioned to capture disproportionate growth.

Other major growth opportunities highlighted in the MRFR report include integration of closed-loop neuromodulation platforms to adjust therapy autonomously, development of prescription digital therapeutics that reduce payer costs by 20--30% compared to traditional interventional pain procedures, and expansion of tailored chronic pain therapy in emerging markets with high growth rates where insurance expansion and national essential medicines list updates ensure a baseline demand for non-pharmacological pain relief and multimodal analgesia approaches.